Using GPCRs as molecular beacons to target ovarian cancer with nanomedicines
Loading...
Authors
Khetan, Riya
Dharmayanti, Cintya
Gillam, Todd A.
Klingler-Hoffmann, Manuela
Ricciardelli, Carmela
Oehler, Martin K.
Blencowe, Anton
Garg, Sanjay
Albrecht, Hugo
Author (Corporation)
Publication date
10.05.2022
Typ of student thesis
Course of study
Collections
Type
01A - Journal article
Editors
Editor (Corporation)
Supervisor
Parent work
Cancers
Special issue
DOI of the original publication
Link
Series
Series number
Volume
14
Issue / Number
10
Pages / Duration
Patent number
Publisher / Publishing institution
MDPI
Place of publication / Event location
Basel
Edition
Version
Programming language
Assignee
Practice partner / Client
Abstract
The five-year survival rate for women with ovarian cancer is very poor despite radical cytoreductive surgery and chemotherapy. Although most patients initially respond to platinum-based chemotherapy, the majority experience recurrence and ultimately develop chemoresistance, resulting in fatal outcomes. The current administration of cytotoxic compounds is hampered by dose-limiting severe adverse effects. There is an unmet clinical need for targeted drug delivery systems that transport chemotherapeutics selectively to tumor cells while minimizing off-target toxicity. G protein-coupled receptors (GPCRs) are the largest family of membrane receptors, and many are overexpressed in solid tumors, including ovarian cancer. This review summarizes the progress in engineered nanoparticle research for drug delivery for ovarian cancer and discusses the potential use of GPCRs as molecular entry points to deliver anti-cancer compounds into ovarian cancer cells. A newly emerging treatment paradigm could be the personalized design of nanomedicines on a case-by-case basis.
Keywords
GPCR, Ovarian cancer, Chemoresistance, Chemotherapy
Subject (DDC)
Event
Exhibition start date
Exhibition end date
Conference start date
Conference end date
Date of the last check
ISBN
ISSN
2072-6694
Language
English
Created during FHNW affiliation
Yes
Strategic action fields FHNW
Publication status
Published
Review
Peer review of the complete publication
Open access category
Gold
License
Citation
Khetan, R., Dharmayanti, C., Gillam, T. A., Kübler, E., Klingler-Hoffmann, M., Ricciardelli, C., Oehler, M. K., Blencowe, A., Garg, S., & Albrecht, H. (2022). Using GPCRs as molecular beacons to target ovarian cancer with nanomedicines. Cancers, 14(10). https://doi.org/10.3390/cancers14102362